2,2′-{[2-(Pyridin-2-yl)-1,3-diazinane-1,3-diyl]bis(methylene)}diphenol

Por Bortoluzzi, Adailton J., Terra, Geovana G.
Publicado em 2012

Di-μ-chlorido-bis­{[2-({[2-(2-pyrid­yl)eth­yl](2-pyridylmeth­yl)amino}meth­yl)phenol]zinc(II)} bis­(perchlorate) dihydrate

Por Coelho, Sara E., Terra, Geovana G., Bortoluzzi, Adailton J.
Publicado em 2010

2-Phenyl-5-(trifluoro­meth­yl)pyrazol-3(2H)-one

Por Gallardo, Hugo, Girotto, Edivandro, Bortoluzzi, Adailton J., Terra, Geovana G.
Publicado em 2009

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials

Por Liu, Jie, Pong, Annpey, Gallo, Silvina, Darekar, Amanda, Terra, Steven G.
Publicado no Cardiovasc Diabetol (2019)

Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

Por Aronson, Ronnie, Frias, Juan, Goldman, Allison, Darekar, Amanda, Lauring, Brett, Terra, Steven G.
Publicado no Diabetes Obes Metab (2018)

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials

Por Gallo, Silvina, Calle, Roberto A., Terra, Steven G., Pong, Annpey, Tarasenko, Lisa, Raji, Annaswamy
Publicado no Diabetes Ther (2020)

Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus

Por Heymsfield, Steven B., Raji, Annaswamy, Gallo, Silvina, Liu, Jie, Pong, Annpey, Hannachi, Hakima, Terra, Steven G.
Publicado no Obesity (Silver Spring) (2020)

Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial

Por Gallo, Silvina, Charbonnel, Bernard, Goldman, Allison, Shi, Harry, Huyck, Susan, Darekar, Amanda, Lauring, Brett, Terra, Steven G.
Publicado no Diabetes Obes Metab (2019)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus

Por Sahasrabudhe, V., Terra, S. G., Hickman, A., Saur, D., Shi, H., O'Gorman, M., Zhou, Z., Cutler, D. L.
Publicado no J Clin Pharmacol (2017)

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials

Por Patel, Shrita, Hickman, Anne, Frederich, Robert, Johnson, Susan, Huyck, Susan, Mancuso, James P., Gantz, Ira, Terra, Steven G.
Publicado no Diabetes Ther (2020)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects

Por Dawra, Vikas Kumar, Liang, Yali, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Cutler, David, Sahasrabudhe, Vaishali
Publicado no Int J Clin Pharmacol Ther (2019)

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

Por Miller, Sam, Krumins, Tania, Zhou, Haojin, Huyck, Susan, Johnson, Jeremy, Golm, Gregory, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado no Diabetes Ther (2018)

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus

Por Liu, Jie, Patel, Shrita, Cater, Nilo B., Wu, Larry, Huyck, Susan, Terra, Steven G., Hickman, Anne, Darekar, Amanda, Pong, Annpey, Gantz, Ira
Publicado no Diabetes Obes Metab (2020)

The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency

Por Dai, Haiqing, Johnson, Susan L, Terra, Steven G, Marbury, Thomas C, Smith, William B, Alcorn, Harry, Boyd, Rebecca A, Wang, Rong, Nguyen, Tu T
Publicado em 2011

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

Por Grunberger, George, Camp, Sarah, Johnson, Jeremy, Huyck, Susan, Terra, Steven G., Mancuso, James P., Jiang, Zhi Wei, Golm, Gregory, Engel, Samuel S., Lauring, Brett
Publicado no Diabetes Ther (2017)

Bioequivalence of Ertugliflozin/Metformin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components

Por Dawra, Vikas Kumar, Liang, Yali, Wei, Hua, Pelletier, Kathleen, Shi, Haihong, Hickman, Anne, Bass, Almasa, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Sahasrabudhe, Vaishali
Publicado no Clin Pharmacol Drug Dev (2019)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Por Fediuk, Daryl J., Nucci, Gianluca, Dawra, Vikas Kumar, Cutler, David L., Amin, Neeta B., Terra, Steven G., Boyd, Rebecca A., Krishna, Rajesh, Sahasrabudhe, Vaishali
Publicado no Clin Pharmacokinet (2020)

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

Por Hollander, Priscilla, Liu, Jie, Hill, Julie, Johnson, Jeremy, Jiang, Zhi Wei, Golm, Gregory, Huyck, Susan, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado no Diabetes Ther (2017)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects

Por Dawra, Vikas Kumar, Cutler, David L., Zhou, Susan, Krishna, Rajesh, Shi, Haihong, Liang, Yali, Alvey, Christine, Hickman, Anne, Saur, Didier, Terra, Steven G., Sahasrabudhe, Vaishali
Publicado no Clin Pharmacol Drug Dev (2018)

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin

Por Sahasrabudhe, Vaishali, Fediuk, Daryl J., Matschke, Kyle, Shi, Haihong, Liang, Yali, Hickman, Anne, Bass, Almasa, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Dawra, Vikas K.
Publicado no Clin Pharmacol Drug Dev (2018)